FDA approvals in the past week range from a new biosimilar to a novel biologic and a significant new claim for an antidiabetic first approved in 2010, and showcased the application of formulation technology to reduce problem side effects and improve convenience of available drugs.
US Approvals Roundup: Cyltezo Biosimilar, Victoza CV Benefit, Gocovri In PD, Kedrab Rabies Biologic, Gout Combo Duzallo
FDA's clearances showcase the application of formulation technology to reduce problem side effects and improve convenience of available drugs.
